Presentation is loading. Please wait.

Presentation is loading. Please wait.

Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience  Maria Teresa Congedo, MD, Alfredo Cesario,

Published byPierce Wilkinson Modified over 5 years ago

Similar presentations

Presentation on theme: "Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience  Maria Teresa Congedo, MD, Alfredo Cesario,"— Presentation transcript:

1 Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience  Maria Teresa Congedo, MD, Alfredo Cesario, MD, Filippo Lococo, MD, Chiara De Waure, MD, Giovanni Apolone, PhD, Elisa Meacci, MD, Sergio Cavuto, MD, Pierluigi Granone, PhD  The Journal of Thoracic and Cardiovascular Surgery  Volume 144, Issue 2, Pages (August 2012) DOI: /j.jtcvs Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

2 Figure 1 Survival: Overall survival of the entire cohort of patients (A), local disease-free survival (L-DFS) (B), and distant disease-free survival (D-DFS) (C). LTS, Long-term survival. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

3 Figure 2 Long-term survival (LTS) (A) and local disease-free survival (L-DFS) (B) according with the completeness of resection. Long-term survival (C) and distant disease-free survival (D-DFS) (D) according to the presence of a weight loss (>10% in the last 6 months before treatment). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

4 Figure 3 Prognostic factors after multimodal treatment for oligometastatic; pathologic N status (A) and adjuvant therapy (B) are related to local disease-free survival (L-DFS) whereas the choice of surgical resection of the distant metastases (C) and the execution of whole brain radiation (D) seem to significantly influence the distant disease-free survival (D-DFS). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

5 Figure 4 The prognostic role of fluorodeoxyglucose positron emission tomographic–computed tomographic (PET–CT) scan: impact on long-term survival (LTS) (A) and distant disease-free survival (D-DFS) (B). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2012 The American Association for Thoracic Surgery Terms and Conditions

Download ppt "Surgery for oligometastatic non–small cell lung cancer: Long-term results from a single center experience  Maria Teresa Congedo, MD, Alfredo Cesario,"

Similar presentations

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma  Kazuya Takamochi, MD, Shiaki Oh, MD,
Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?  Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,

Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?  Atsushi Watanabe, MD, PhD, Tetsuya Higami, MD, PhD, Syunsuke Ohori,
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 

One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
Surgical Treatment in Patient with Non–Small-Cell Lung Cancer with Fissure Involvement: Anatomical versus Nonanatomical Resection  Giovanni Leuzzi, MD,

Surgical Treatment in Patient with Non–Small-Cell Lung Cancer with Fissure Involvement: Anatomical versus Nonanatomical Resection  Giovanni Leuzzi, MD,
Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,
Long-Term Results after Treatment for Recurrent Thymoma: A Multicenter Analysis  Alberto Sandri, Giacomo Cusumano, Filippo Lococo, MD, Marco Alifano, Pierluigi.

Long-Term Results after Treatment for Recurrent Thymoma: A Multicenter Analysis  Alberto Sandri, Giacomo Cusumano, Filippo Lococo, MD, Marco Alifano, Pierluigi.
A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients 

A follow-up of integrated positron emission tomography/computed tomography after curative resection of non–small-cell lung cancer in asymptomatic patients 
Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer?  Traves D. Crabtree, MD, Varun Puri,

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer?  Traves D. Crabtree, MD, Varun Puri,
Malignant Solitary Fibrous Tumors of the Pleura: Retrospective Review of a Multicenter Series  Filippo Lococo, MD, Alfredo Cesario, MD, Giuseppe Cardillo,

Malignant Solitary Fibrous Tumors of the Pleura: Retrospective Review of a Multicenter Series  Filippo Lococo, MD, Alfredo Cesario, MD, Giuseppe Cardillo,
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.
Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients 

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients 
Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.

Multimodality Treatment of Stage III Non-small Cell Lung Cancer: Analysis of a Phase II Trial Using Preoperative Cisplatin and Gemcitabine with Concurrent.
Pleomorphic carcinoma of the lung: A surgical outcome

Pleomorphic carcinoma of the lung: A surgical outcome
Lung hernia after en bloc cervicothoracic resection

Lung hernia after en bloc cervicothoracic resection
The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer  Kyong-Ah Yoon,
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
Multimodality treatment of unresectable stage III non–small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent.

Multimodality treatment of unresectable stage III non–small cell lung cancer: Interim analysis of a phase II trial with preoperative gemcitabine and concurrent.
Intrinsic cardiac stem cells are essential for regeneration

Intrinsic cardiac stem cells are essential for regeneration
Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.

Similar presentations

Ads by Google